BenchSci Raises $22 Million Series B and Launches New AI-Assisted Reagent Selection Product to Optimize $10.2 Billion in Life Science R&D Spend F-Prime Capital led the round with participation from existing investors including Gradient Ventures, Google’s AI fund. TORONTO, February 4, 2020-- BenchSci, which uses machine learning to identify and resolve preclinical research inefficiencies in drug discovery, announced today it has raised $22 million in Series B financing, launched its new AI-Assisted Reagent Selection product, and expanded its contract with Novartis in a market worth more than $10.2 billion per year in life science R&D cost-saving opportunities.